Palo Alto Investors’s Puma Biotechnology PBYI Stock Holding History

Palo Alto Investors’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,392,997	Closed	-$9.77M	–	39
2021 Q3	$9.77M	Hold	1,392,997	–	–	0.59%	24
2021 Q2	$12.8M	Hold	1,392,997	–	–	0.7%	21
2021 Q1	$13.5M	Buy	1,392,997 +19,100	+1%	+$213K	0.77%	21
2020 Q4	$14.1M	Buy	1,373,897 +5,580	+0.4%	+$56.5K	0.74%	20
2020 Q3	$13.8M	Buy	1,368,317 +24,420	+2%	+$249K	0.76%	19
2020 Q2	$14M	Sell	1,343,897 -52,266	-4%	-$541K	0.84%	20
2020 Q1	$11.8M	Buy	1,396,163 +46,983	+3%	+$456K	0.99%	19
2019 Q4	$11.8M	Sell	1,349,180 -56,500	-4%	-$468K	0.65%	21
2019 Q3	$15.1M	Hold	1,405,680	–	–	1.01%	21
2019 Q2	$17.9M	Buy	1,405,680 +224,900	+19%	+$5.18M	0.87%	22
2019 Q1	$45.8M	Buy	1,180,780 +20,880	+2%	+$638K	1.91%	17
2018 Q4	$23.6M	Buy	+1,159,900	New	+$34.8M	1.26%	20

Other funds holding PBYI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Palo Alto Investors's PBYI Position: Q4 2021 in Review

Palo Alto Investors sold out of Puma Biotechnology (PBYI) in Q4 2021, closing a stake of 1,392,997 shares — an estimated $9.77M sold.

Palo Alto Investors first reported a position in PBYI in Q4 2018 and held it in 12 quarters. The position peaked at $45.8M in Q1 2019. 102 funds tracked by Wall St. Rank hold PBYI as of Q4 2021.

Palo Alto Investors reported no remaining Puma Biotechnology position as of Q4 2021 after selling out during the quarter.
Palo Alto Investors sold 1,392,997 Puma Biotechnology shares in Q4 2021, an estimated $9.77M.
Palo Alto Investors first reported a position in Puma Biotechnology in Q4 2018 and held it in 12 quarters.
Palo Alto Investors's Puma Biotechnology position peaked at $45.8M in Q1 2019.
102 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2021.

Based on Palo Alto Investors's 13F filing for Q4 2021, filed 14 Feb 2022.